文献速递系统性红斑狼疮

减毒带状疱疹疫苗在系统性红斑狼疮患者中的安全性与免疫应答:随机安慰剂对照试验

Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2019-09-17

该随机安慰剂对照试验纳入90例SLEDAI<6且免疫抑制治疗稳定≥6个月的成人SLE患者,按1:1接受Zostavax或安慰剂。疫苗组抗VZV IgG及VZV刺激IFN-γ分泌T细胞斑点较安慰剂组显著升高,注射部位反应更多但均为自限性,未发生带状疱疹。

要点

  • 稳定期SLE患者接种Zostavax可显著提高抗VZV IgG及细胞免疫应答
  • 疫苗组注射部位反应多于安慰剂组,但均为自限性
  • 6周内无带状疱疹发生,SLE flare轻微且两组相近

核心结论

  • 在未接受强化免疫抑制的稳定期SLE患者中,Zostavax耐受良好并可激发免疫应答。

研究设计与样本

  • 随机安慰剂对照试验纳入90例SLEDAI<6且免疫抑制治疗稳定≥6个月的成人SLE患者,按1:1分配至Zostavax或安慰剂。
  • 基线及第6周采用酶联荧光法测抗VZV IgG,采用VZV刺激IFN-γ酶联ELISPOT法评估细胞免疫应答。

主要发现

  • 抗VZV IgG从0周到6周变化疫苗组为+59.8%、安慰剂组为-2.1%。
  • 第6周抗VZV IgG经基线校正后疫苗组显著高于安慰剂组(4.16±1.26 vs 3.32±1.01;p<0.001)。
  • IFN-γ分泌T细胞斑点安慰剂组减少17%、疫苗组增加42%。
  • 第6周T细胞斑点经基线校正后疫苗组显著高于安慰剂组(38.1±78.2 vs 23.1±47.9;p=0.02)。
  • 注射部位自限性反应疫苗组31%显著多于对照组7%(p<0.01),6周内无患者发生带状疱疹。

临床怎么用

  • 对SLEDAI<6且免疫抑制治疗稳定≥6个月的SLE患者,可考虑接种Zostavax以激发抗VZV免疫应答。

局限性

  • 研究未纳入接受强化免疫抑制治疗的SLE患者,结果不能外推至该人群。
  • 随访免疫应答至第6周,未报告更长期保护效力数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the safety and immunogenicity of a live-attenuated herpes zoster (HZ) vaccine in patients with systemic lupus erythematosus (SLE). METHODS: Adult SLE patients having a SLEDAI <6 and stable immunosuppressive treatment for ≥6 months were recruited. Participants were randomly assigned to receive HZ vaccine (Zostavax) or placebo injection. Anti-varicella zoster virus (VZV) IgG reactivity (baseline and week 6) was measured by an enzyme-linked fluorescence assay. Cell-mediated response was assessed by a VZV-stimulated interferon-gamma (IFN-γ) enzyme-linked ELISPOT assay. Adverse events and immune responses of the two groups were compared. RESULTS: 90 SLE patients were recruited (age 45.6±14.1 years; 93% women) and assigned to Zostavax or placebo (in 1:1 ratio). Baseline clinical parameters were similar between the two groups. The change in anti-VZV IgG from week 0 to 6 was +59.8% in the vaccine and -2.1% in the placebo group. Week 6 anti-VZV IgG was significantly higher in vaccinated than placebo-treated patients, after adjustment for baseline (4.16±1.26 vs 3.32±1.01; p<0.001). The number of IFN-γ secreting T-cell spots decreased in the placebo-treated patients (-17%) but increased in vaccinated patients (+42%). The T-cell spots number at week 6 was significantly higher in vaccine-than placebo-treated patients after adjustment for baseline (38.1±78.2 vs 23.1±47.9; p=0.02). Significantly more vaccinated patients reported self-limiting injection site reaction than controls (31% vs 7%; p<0.01). Two vaccinated patients (4.4%) and one (2.2%) placebo-treated patient had mild/moderate SLE flares but no patients developed HZ eruption within 6 weeks postvaccination. CONCLUSIONS: In patients with stable SLE not receiving intensive immunosuppression, Zostavax was well-tolerated and provoked an immune response. TRIAL REGISTRATION NUMBER: US ClinicalTrials.gov registry (NCT02477150).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mok CC, Chan KH, Ho LY, et al. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial. Ann Rheum Dis. 2019. PMID: 31530556. doi:10.1136/annrheumdis-2019-215925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。